Lexeo Therapeutics appoints Tim Van Hauwermeiren, argenx CEO, to Board

Lexeo Therapeutics, Inc.

Appointment effective July 5, 2024; term expires at 2027 annual meeting.
Standard director comp: $40k annual cash, initial option for 36,000 shares, annual option for 18,000 shares.
Van Hauwermeiren is co-founder and CEO of argenx; built company to ~$25B market cap.
No arrangements or family relationships with Lexeo officers; standard indemnification agreement.
Appointed as independent, non-executive director.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Tim Van Hauwermeiren

Director

LXEO · Lexeo Therapeutics, Inc.

Effective: 2024-07-05
Filed: July 8, 2024, 7:59 PM ET

On July 5, 2024 (the “Appointment Date”), Tim Van Hauwermeiren was appointed to the board of directors (the “Board”) of Lexeo Therapeutics, Inc. (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Tim Van Hauwermeiren was appointed as Director at Lexeo Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On July 5, 2024 (the “Appointment Date”), Tim Van Hauwermeiren was appointed to the board of directors (the “Board”) of Lexeo Therapeutics, Inc. (the “Company”).

View on SEC.gov

Lexeo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-081942

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.